Treatment of Chronic Mountain Sickness

• Status: Recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: Male

Summary

This study aims to assess the effect of two drugs for the treatment of chronic mountain sickness in highlanders.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre d'Expertise sur l'Altitude EXALT; Centre d’Expertise sur l’Altitude EXALT
• Treatments: Acetazolamide; Atorvastatin

Criteria

Inclusion Criteria:

• Male

• Age between 18 and 55 yrs

• Body mass index <30kg/m²

• Born at >3500 m, living for >3 years at the local high altitude

• No diagnosis of cardiorespiratory, metabolic or neurological diseases

• No drug intake

• No smoker

• Chronic mountain sickness score ≥6

Exclusion Criteria:

• Diagnosis of cardiorespiratory, metabolic and neurological diseases

• Systolic > 130 mmHg and/or diastolic > 85 mmHg blood pressure

• Drug intake

• Smoker

• Chronic mountain sickness score <6